Last reviewed · How we verify
PRISTINAMYCIN XRP7263
Pristinamycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Pristinamycin (XRP7263), developed by Sanofi, is a broad-spectrum antibiotic with activity against Gram-positive bacteria. It has been studied for treating acute community-acquired pneumonia but lacks an FDA label. One terminated Phase 4 trial compared it to amoxicillin.
At a glance
| Generic name | PRISTINAMYCIN XRP7263 |
|---|---|
| Also known as | Pyostacine ® |
| Sponsor | Sanofi |
| Drug class | Macrolide antibiotic / Streptogramin |
| Target | Bacterial 50S ribosomal subunit |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Pristinamycin is a streptogramin-type macrolide antibiotic composed of two components (pristinamycin I and II) that work synergistically to inhibit bacterial protein synthesis. It binds to the bacterial 50S ribosomal subunit, preventing peptide bond formation and translation. This bactericidal activity makes it effective against a range of gram-positive bacteria and some gram-negative organisms.
Approved indications
- Bacterial infections caused by susceptible gram-positive organisms
- Respiratory tract infections
- Skin and soft tissue infections
Common side effects
- Gastrointestinal disturbances
- Nausea
- Diarrhea
- Abdominal pain
- Hypersensitivity reactions
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PRISTINAMYCIN XRP7263 CI brief — competitive landscape report
- PRISTINAMYCIN XRP7263 updates RSS · CI watch RSS
- Sanofi portfolio CI